European Prostate Cancer Diagnostic and Therapeutic Market to Reach $10,430.3 Million by 2035

European prostate cancer diagnostic and therapeutic market was valued at $4,671.4 million in 2025 and is projected to reach $10,430.3 million by 2035, growing at a CAGR of 8.4% during the forecast period (2026–2035). Demographic trends and disease burden remain a key driver shaping forecasts for the European prostate cancer diagnostic and therapeutic market. According to Organisation for Economic Co-operation and Development and European Joint Research Centre for 2025, prostate cancer incidence rates across the EU average around 154 new cases per 100,000 men, with significant inter-country variation reflecting differences in screening uptake and health system capacity. Prostate cancer accounts for nearly one in four new cancers diagnosed in men across Europe, highlighting its dominant role in male oncology caseloads and underpinning demand for early detection tools such as PSA testing, multiparametric MRI, PSMA-PET imaging, and targeted biopsy procedures.

Browse the full report description of “European Prostate Cancer Diagnostic and Therapeutic Market Size, Share & Trends Analysis Report by Diagnostic Technique (Prostate-Specific Antigen Test, Digital Rectal Examination, Prostate Biopsy, Imaging Techniques) by Therapeutics (Hormonal Therapy, Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy, Surgery) Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/european-prostate-cancer-diagnostic-therapeutic-market

An ageing male population further amplifies this effect as risk increases sharply with age, particularly beyond 60 years, driving higher volumes of diagnostic imaging and pathology workflows. Incremental increases in annual incidence directly expand treatment caseloads, supporting demand for surgical, radiotherapy and systemic therapy solutions across established healthcare providers. These epidemiological metrics from authoritative sources inform volume and utilization assumptions in market models, strengthening the reliability of revenue projections for both diagnostics and therapeutics.

Key Leaders Transforming the European Prostate Cancer Diagnostic and Therapeutic Market

The key players in the European prostate cancer diagnostic and therapeutic market include Roche, Johnson & Johnson, Pfizer, Novartis, Astellas Pharma, among others. Companies operating in the European prostate cancer diagnostic and therapeutic market are advancing innovation through enhanced molecular testing, precision imaging technologies, and next-generation targeted therapies. Continued investment in biomarker research, radioligand treatments, and minimally invasive surgical systems is improving diagnostic accuracy and clinical outcomes.

• In June 2025, FUJIFILM Healthcare Europe partnered with Ibex Medical Analytics to integrate Ibex’s AI platform with Fujifilm’s SYNAPSE Pathology solution. This collaboration aims to improve the efficiency and accuracy of cancer diagnosis, including prostate cancer, by streamlining digital pathology workflows and reducing turnaround times for pathology results.
• In 2025, the EU4Health programme launched a call for proposals to pilot and implement enhanced prostate cancer screening initiatives across European member states. With a total budget of over €7 million ($8.2 million), this funding round is designed to support earlier detection efforts, improve screening infrastructure, and encourage adoption of best practices at the regional level.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Diagnostic Technique
  • By Therapeutics
• Competitive Landscape - Roche, Johnson & Johnson, Pfizer, Novartis, Astellas Pharma, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

European Prostate Cancer Diagnostic and Therapeutic Market Report Segment

By Diagnostic Technique

• Prostate-Specific Antigen Test
• Digital Rectal Examination
• Prostate Biopsy
• Imaging Techniques

By Therapeutics

• Hormonal Therapy
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Targeted Therapy
• Surgery

European Prostate Cancer Diagnostic and Therapeutic Market Report Segment by Country

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/european-prostate-cancer-diagnostic-therapeutic-market